Enduring Present Approaches to Testing: Noninvasive Biomarkers in Liver Disease

Course overview

This webinar will review the latest evidence, guideline recommendations, interpretation strategies, and testing solutions to support accurate disease classification, reduce reliance on liver biopsy, and improve confidence in differentiating metabolic from alcohol-related liver injury. Learning Objectives: 1. Discuss the growing prevalence and incidence of MASLD and MASH in the U.S. and their impact on the healthcare system. 2. Summarize the risk factors and comorbid conditions associated with MASLD and MASH, and the impact of these conditions on the progression and management of liver disease. 3. Recognize the role of noninvasive testing in the diagnosis and management of MASLD and MASH based on key recommendations from several U.S. guidelines. 4. Differentiate metabolic and alcohol-related liver disease using objective PEth biomarker thresholds to identify MASLD, MetALD, and ALD phenotypes. 5. Apply current best practices for noninvasive biomarker testing to guide work-up, diagnosis, and interdisciplinary treatment planning for patients with liver disease.